Are P2Y12 inhibitors superior to aspirin for long-term secondary prevention of cardiovascular disease?

Expert Rev Cardiovasc Ther. 2023 May;21(5):305-309. doi: 10.1080/14779072.2023.2199155. Epub 2023 Apr 6.

Authors

Stephanie Carlin^{1

2}, John Eikelboom^{1

2

3}

Affiliations

¹ Thrombosis Service, Hamilton General Hospital, Hamilton, Canada.
² Department of Medicine, McMaster University, Hamilton, Canada.
³ Population Health Research Institute, Hamilton, Canada.

PMID: 37010071
DOI: 10.1080/14779072.2023.2199155

No abstract available

Keywords: P2Y12 receptor antagonists; antiplatelet agents; aspirin; cardiovascular disease; secondary prevention.

Publication types

Editorial

MeSH terms

Aspirin* / therapeutic use
Cardiovascular Diseases* / drug therapy
Cardiovascular Diseases* / prevention & control
Clopidogrel
Drug Therapy, Combination
Humans
Platelet Aggregation Inhibitors / therapeutic use
Purinergic P2Y Receptor Antagonists / therapeutic use
Receptors, Purinergic P2Y12
Secondary Prevention

Substances

Aspirin
Platelet Aggregation Inhibitors
Clopidogrel
Purinergic P2Y Receptor Antagonists
Receptors, Purinergic P2Y12